KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Receivables (2018 - 2025)

Moderna (MRNA) has disclosed Change in Receivables for 8 consecutive years, with -$859.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 28.77% to -$859.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$156.0 million, a 70.79% increase, with the full-year FY2025 number at -$156.0 million, up 70.79% from a year prior.
  • Change in Receivables was -$859.0 million for Q4 2025 at Moderna, down from $1.0 billion in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 billion in Q1 2021 to a low of -$1.3 billion in Q4 2022.
  • A 5-year average of -$59.4 million and a median of -$151.0 million in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 90850.0% in 2021, then crashed 27100.0% in 2023.
  • Moderna's Change in Receivables stood at $33.0 million in 2021, then plummeted by 4069.7% to -$1.3 billion in 2022, then grew by 25.65% to -$974.0 million in 2023, then dropped by 23.82% to -$1.2 billion in 2024, then increased by 28.77% to -$859.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Change in Receivables are -$859.0 million (Q4 2025), $1.0 billion (Q3 2025), and -$30.0 million (Q2 2025).